Ahren Innovation Capital has led a $16m initial series A tranche for Mogrify, co-founded by researchers from Bristol, Monash and Duke universities.
University of Colorado-founded IM Therapeutics has received $10m from investors including the university's Healthcare Innovation Fund to advance a treatment for type 1 diabetes.
UVC Partners returned to back Fazua together with the electric bike drive system maker's other existing investors and an EIB-run venture debt provider.
University of Bristol-founded voice and intelligent control semiconductor developer Xmos has increased its total funding to $91m following a $19m round.
Gum disease vaccine developer Denteric has spun out of Melbourne with series A capital from the institution, the Biomedical Translation Fund and CSL.
Curamir Therapeutics, a cancer therapeutics developer exploiting Suny research into microRNA, has made its formal debut with $10m of series A funding.
Cash Capital co-led a series A for Vision Medicals, co-founded by faculty at the Yunnan Province Key Laboratory for Gene Editing.
ETH Zurich’s Versantis picked up series B funding from Zürcher Kantonalbank among other returning investors to bring its total to $20.6m.